Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Study to Investigate the Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age.

Next Previous
Trial Profile

An Open Label Study to Investigate the Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Nov 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Raltegravir (Primary) ; Emtricitabine/tenofovir
  • Indications HIV-1 infections
  • Focus Pharmacokinetics; Therapeutic Use

Most Recent Events

  • 20 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 05 Apr 2013 Accrual to date is 105% according to United Kingdom Clinical Research Network.
  • 31 May 2012 Planned end date changed from 1 Jan 2012 to 20 Apr 2012 as reported by United Kingdom Clinical Research Network.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top